EORTC/TROG 01.03 - Glioblastoma/Temozolomide - 26981/22981

By w.paterson
August 14, 2021
0 Comments

Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme. A Randomized Phase III Study

Primary Sponsor

EORTC

Collaborating Groups

TROG Cancer Research

October 18, 2022

NINJA Radiation Therapy Trial participant tells his journey to treatment

The journey to becoming the 200th participant for the

September 6, 2022

The gift that kept on giving

The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing

Join us to raise $25,000

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme. A Randomized Phase III Study

TROG 01.04 – Rectal (Phase III)

EORTC 22996-24002/TROG 01.01 – EPO Head & Neck

Related Post

NINJA Radiation Therapy Trial participant tells his journey to treatment

The gift that kept on giving

Join us to raise $25,000

EORTC/TROG 01.03 – Glioblastoma/Temozolomide – 26981/22981

Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme. A Randomized Phase III Study

TROG 01.04 – Rectal (Phase III)

EORTC 22996-24002/TROG 01.01 – EPO Head & Neck

Related Post

NINJA Radiation Therapy Trial participant tells his journey to treatment

The gift that kept on giving

Join us to raise $25,000